SVSeyed Ehsan Vasegh

Seyed Ehsan Vasegh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Seyed Ehsan Vasegh has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mistrafficking of KCC2 promotes hyperexcitability in hippocampal circuitry in a murine model of Christianson Syndrome

    by Jamie Mustian, Haoyi Qiu, Andy Yl Gao, Cong Loc Dang, Seyed Ehsan Vasegh, Bastien Castagner, John Orlowski, Reza Sharif-Naeini, R. Anne McKinney

    How endosomal trafficking shapes inhibitory neurotransmission remains poorly understood, despite both processes being linked independently to epilepsy and neurodevelopmental disease. Christianson syndrome (CS), an X-linked neurodevelopmental disorder, represents a potential tractable condition to investigate such coupled processes. CS is caused by loss-of-function mutations in the SLC9A6 gene which encodes the organellar (Na+, K+)/H+ exchanger NHE6 isoform whose loss overacidifies recycling endosomes and disrupts cargo delivery. Prior work has emphasized NHE6's role in excitatory neurons and glia; whether endosomal dysfunction reshapes inhibitory circuits and thereby drives the early treatment-resistant epilepsy that defines CS has not been addressed. Using Nhe6 -/Y mice, we identify a previously unrecognized endosomal-to-inhibitory axis: NHE6 is required for the surface delivery and stability of the neuron-specific potassium-chloride co-transporter KCC2 (encoded by SLC12A5 ) that sets the driving force for GABAergic inhibition. Loss of NHE6 produces developmental downregulation and mistargeting of KCC2 in hippocampal neurons, impaired chloride homeostasis, and circuit-level hyperexcitability in response to a subthreshold convulsant challenge. These results recast CS epilepsy not as a downstream consequence of excitatory dysfunction but as a primary failure of inhibitory development driven by endosomal mistrafficking. More broadly, they establish endosomal pH regulation as a determinant of KCC2 biology; a node implicated across genetic and acquired epilepsies. Pharmacologically restoring KCC2 function therefore offers a mechanism-based therapeutic strategy for CS, and likely for the broader class of disorders in which endosomal trafficking and inhibitory imbalance converge.

  • Open Access

    Inositol Thiophosphates as Inhibitors of Mammalian, Plant, and Fungal Phytases

    by Seyed Ehsan Vasegh, Rebecca Cummer, Justin Meneses, Lie Von Kok, Lauren M. Finn, Valentin Nelea, Lharbi Dridi, Bettina G. Keller, Dieter P. Reinhardt, Bastien Castagner

    Inositol phosphates constitute a conserved family of signaling molecules that regulate a wide range of cellular processes such as energy metabolism, calcium release, and signal transduction. In mammalian cells, the endoplasmic reticulum-localized enzyme, multiple inositol polyphosphate phosphatase 1 (MINPP1), is the sole phytase known to hydrolyze myo-inositol hexakisphosphate (IP6). MINPP1 is critical for maintaining intracellular inositol phosphate homeostasis, and its dysfunction is linked to severe neurodevelopmental disorders. Beyond mammals, phytases are widely distributed across bacteria, plants, and fungi, where they play essential roles in phosphorus recycling and have important commercial applications in agriculture and animal feed by improving nutrient availability. Despite this broad biological and economic significance, selective chemical tools to study MINPP1 and other phytases, as well as to probe their activity, remain limited. Here, we report the evaluation of the inositol thiophosphates, myo-inositol pentakisthiophosphate (IT5) and hexakisthiophosphate (IT6), as inhibitors of phytases. We show that IT5 and IT6 are resistant to MINPP1 hydrolysis, whereas the native substrates are readily processed, with myo-inositol pentakisphosphate (IP5) hydrolyzed faster than IP6. Both IT5 and IT6 act as potent MINPP1 inhibitors, with nanomolar IC50 values, and display enhanced binding affinities and slower dissociations relative to IP6. Additionally, IT6 inhibits phytases from the plant and fungal kingdoms, including wheat, yeast, and Aspergillus niger, demonstrating cross-kingdom inhibitory activity. Together, these results establish IT6 as a high-affinity, nonhydrolyzable phytase inhibitor and position IT6 as a useful chemical probe for the study of phytases.

  • Structure–Activity Relationship of Inositol Thiophosphate Analogs as Allosteric Activators of Clostridioides difficile Toxin B

    by Rebecca Cummer, Félix Grosjean, Raphaël Bolteau, Seyed Ehsan Vasegh, Simon Veyron, Liam Keogh, Jean-François Trempe, Bastien Castagner

    Clostridioides difficile is a bacterium that causes life-threatening intestinal infections. Infection symptoms are mediated by a toxin secreted by the bacterium. Toxin pathogenesis is modulated by the intracellular molecule, inositol-hexakisphosphate (IP6). IP6 binds to a cysteine protease domain (CPD) on the toxin, inducing autoproteolysis, which liberates a virulence factor in the cell cytosol. We developed second-generation IP6 analogs designed to induce autoproteolysis in the gut lumen, prior to toxin uptake, circumventing pathogenesis. We synthesized a panel of thiophosphate-/sulfate-containing IP6 analogs and characterized their toxin binding affinity, autoproteolysis induction, and cation interactions. Our top candidate was soluble in extracellular cation concentrations, unlike IP6. The IP6 analogs were more negatively charged than IP6, which improved affinity and stabilization of the CPD, enhancing toxin autoproteolysis. Our data illustrate the optimization of IP6 with thiophosphate biomimetic which are more capable of inducing toxin autoproteolysis than the native ligand, warranting further studies in vivo.


  • Open Access

    Structure-activity relationship of inositol thiophosphate analogs as allosteric activators of Clostridioides difficile toxin B

    by Rebecca Cummer, Félix Grosjean, Raphaël Bolteau, Seyed Ehsan Vasegh, Simon Veyron, Liam Keogh, Jean-François Trempe, Bastien Castagner

    Clostridioides difficile is a bacterium that causes life-threatening intestinal infections. Infection symptoms are mediated by a toxin secreted by the bacterium. Toxin pathogenesis is modulated by the intracellular molecule, inositol-hexakisphosphate (IP6). IP6 binds to a cysteine protease domain (CPD) on the toxin, inducing auto-proteolysis, which liberates a virulence factor in the cell cytosol. We developed second-generation IP6 analogs designed to induce auto-proteolysis in the gut lumen, prior to toxin uptake, circumventing pathogenesis. We synthesized a panel of thiophosphate-/sulfate-containing IP6 analogs, and characterized their toxin binding affinity, auto-proteolysis induction and cation interactions. Our top candidate was soluble in extracellular cation concentrations, unlike IP6. The IP6 analogs were more negatively charged than IP6, which improved affinity and stabilization of the CPD, enhancing toxin auto-proteolysis. Our data illustrate the optimization of IP6 with thiophosphate biomimetics which are more capable of inducing toxin auto-proteolysis than the native ligand, warranting further studies in vivo.